AR005397A1 - Anticuerpo agonista monoclonal que se liga especificamente al receptor ob, un metodo para mejorar la proliferacion o diferenciacion in vitro de una celula que comprende un receptor ob, el uso de un anticuerpo agonista anti-receptor ob para la preparacion de una dosificacion fisiologicamente aceptable, y metodos para identificar un anticuerpo que se liga o activa al receptor ob que incrementa la proliferacion o diferenciacion de una celula - Google Patents

Anticuerpo agonista monoclonal que se liga especificamente al receptor ob, un metodo para mejorar la proliferacion o diferenciacion in vitro de una celula que comprende un receptor ob, el uso de un anticuerpo agonista anti-receptor ob para la preparacion de una dosificacion fisiologicamente aceptable, y metodos para identificar un anticuerpo que se liga o activa al receptor ob que incrementa la proliferacion o diferenciacion de una celula

Info

Publication number
AR005397A1
AR005397A1 ARP970100078A ARP970100078A AR005397A1 AR 005397 A1 AR005397 A1 AR 005397A1 AR P970100078 A ARP970100078 A AR P970100078A AR P970100078 A ARP970100078 A AR P970100078A AR 005397 A1 AR005397 A1 AR 005397A1
Authority
AR
Argentina
Prior art keywords
receiver
proliferation
differentiation
receptor
agonist
Prior art date
Application number
ARP970100078A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/667,197 external-priority patent/US7074397B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR005397A1 publication Critical patent/AR005397A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Se describe el receptor de WSX y los anticuerpos que se ligan al mismo incluyendo anticuerpos antagonistas y neutralizantes), incluyendo diversos usosde los mismos. LOs usos de los ligandos de WSX ( por ejemplo, anticuerpo agonistascontr a el receptor de WSX o proteína OB) en la hematopoyesis,receptor de WSX, el DEC del receptor, composición que lo comprende, un método para identificar y puificaar una molécula que activa el receptor WSX, unanticuerpo, un fragmento delmismo, uso o d e un anticuerpo y de un ligando de WSX para la preparación de un medicamento, un ácido nucleico aislado, un vector deexpresión, una célula huésped, un proceso para el uso de ácido nucleico, una composición farmacéutica, un artículode fabricac ión y métodos in vitro paraactivar el receptor WSX y realzar la proliferación o diferenciación de una célula.
ARP970100078A 1996-01-08 1997-01-08 Anticuerpo agonista monoclonal que se liga especificamente al receptor ob, un metodo para mejorar la proliferacion o diferenciacion in vitro de una celula que comprende un receptor ob, el uso de un anticuerpo agonista anti-receptor ob para la preparacion de una dosificacion fisiologicamente aceptable, y metodos para identificar un anticuerpo que se liga o activa al receptor ob que incrementa la proliferacion o diferenciacion de una celula AR005397A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58500596A 1996-01-08 1996-01-08
US08/667,197 US7074397B1 (en) 1996-01-08 1996-06-20 Method for enhancing proliferation or differentiation of a cell using ob protein

Publications (1)

Publication Number Publication Date
AR005397A1 true AR005397A1 (es) 1999-04-28

Family

ID=27079271

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP970100078A AR005397A1 (es) 1996-01-08 1997-01-08 Anticuerpo agonista monoclonal que se liga especificamente al receptor ob, un metodo para mejorar la proliferacion o diferenciacion in vitro de una celula que comprende un receptor ob, el uso de un anticuerpo agonista anti-receptor ob para la preparacion de una dosificacion fisiologicamente aceptable, y metodos para identificar un anticuerpo que se liga o activa al receptor ob que incrementa la proliferacion o diferenciacion de una celula
ARP050104868A AR051505A2 (es) 1996-01-08 2005-11-21 Una composicion que comprende un receptor ob variante 12.1, una molecula de acido nucleico que codifica dicho receptor ligado operativamente a un promotor, un vector de expresion, una celula huesped, un receptor ob quimerico fusionado a una inmunoglobulina y anticuerpo agonista monoclonal que se lig
ARP060100522A AR052374A2 (es) 1996-01-08 2006-02-14 Una composicion que comprende un receptor ob variante 12.1, una molecula de acido nucleico que codifica dicho receptor ligado operativamente a un promotor, un vector de expresion, una celula huesped, un receptor ob quimerico fusionado a una inmunologlubina y anticuerpo agonista monoclonal que se lig

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP050104868A AR051505A2 (es) 1996-01-08 2005-11-21 Una composicion que comprende un receptor ob variante 12.1, una molecula de acido nucleico que codifica dicho receptor ligado operativamente a un promotor, un vector de expresion, una celula huesped, un receptor ob quimerico fusionado a una inmunoglobulina y anticuerpo agonista monoclonal que se lig
ARP060100522A AR052374A2 (es) 1996-01-08 2006-02-14 Una composicion que comprende un receptor ob variante 12.1, una molecula de acido nucleico que codifica dicho receptor ligado operativamente a un promotor, un vector de expresion, una celula huesped, un receptor ob quimerico fusionado a una inmunologlubina y anticuerpo agonista monoclonal que se lig

Country Status (10)

Country Link
US (1) US20020193571A1 (es)
EP (2) EP0885299B1 (es)
JP (3) JP2000503204A (es)
AR (3) AR005397A1 (es)
AT (2) ATE307887T1 (es)
AU (1) AU721129B2 (es)
CA (1) CA2241564C (es)
DE (2) DE69739677D1 (es)
IL (2) IL125073A0 (es)
WO (1) WO1997025425A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6451523B1 (en) * 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6977240B1 (en) 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
DK0877803T3 (da) * 1996-01-04 2005-09-19 Amgen Inc OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
ATE307887T1 (de) * 1996-01-08 2005-11-15 Genentech Inc Ob-rezeptor und liganden
US6541604B1 (en) * 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7148004B1 (en) 1997-01-16 2006-12-12 The Rockefeller University Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight
AU2476301A (en) * 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7084252B1 (en) 1996-01-16 2006-08-01 The Rockefeller University DB, the receptor for leptin
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US7619079B2 (en) 1996-02-14 2009-11-17 The Rockefeller University Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
AUPO224696A0 (en) * 1996-09-11 1996-10-03 Amrad Operations Pty. Limited A novel haemopoietin receptor and genetic sequences encoding same
WO1998057177A1 (en) * 1997-06-09 1998-12-17 Regeneron Pharmaceuticals, Inc. Assay systems for leptin-enhancing agents
WO1999036433A2 (en) * 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
SE0000597D0 (sv) * 2000-02-24 2000-02-24 Active Biotech Ab Novel antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
RU2287534C2 (ru) 2000-10-20 2006-11-20 Тугаи Сейяку Кабусики Кайся Деградированное антитело, являющееся агонистом tpo
EP2351838A1 (en) * 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Crosslinking agonistic antibodies
AUPR703601A0 (en) * 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7373356B2 (en) * 2002-08-14 2008-05-13 National Instruments Corporation Transducer specification database
US8158385B2 (en) * 2002-10-11 2012-04-17 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
EP1616880A4 (en) * 2003-03-13 2006-07-26 Chugai Pharmaceutical Co Ltd LIGAND WITH AGONISTIC ACTIVITY AGAINST A MUTED RECEPTOR
JP2004279086A (ja) * 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
EP1609803A4 (en) * 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODY AGAINST CD22 AND APPLICATIONS THEREOF
WO2005030793A2 (en) 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
US20070280951A1 (en) * 2003-12-12 2007-12-06 Naoki Kimura Cell Death Inducing Agents
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
CA2555421A1 (en) * 2004-02-17 2005-09-01 Schering Corporation Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
EP1757686A4 (en) * 2004-04-09 2008-03-12 Chugai Pharmaceutical Co Ltd Cell death inducer
CN101103043A (zh) * 2005-01-06 2008-01-09 诺和诺德公司 Kir结合剂和使用其的方法
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
JPWO2006123724A1 (ja) * 2005-05-18 2008-12-25 国立大学法人徳島大学 抗ｈｌａ抗体を利用した新規医薬品
JP5224580B2 (ja) * 2005-06-10 2013-07-03 中外製薬株式会社 ｓｃ（Ｆｖ）２部位特異的変異体
KR101367544B1 (ko) * 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
KR101360671B1 (ko) * 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
KR20090021217A (ko) * 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 조혈 줄기세포 증가 촉진제
CN101517075A (zh) * 2006-07-13 2009-08-26 中外制药株式会社 细胞死亡诱导剂
JP2009543579A (ja) * 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
JP5822248B2 (ja) * 2009-10-27 2015-11-24 国立大学法人佐賀大学 ノックアウト非ヒト動物
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6187985B2 (ja) * 2015-07-14 2017-08-30 国立大学法人佐賀大学 ノックアウト非ヒト動物
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
US10550192B2 (en) 2016-11-08 2020-02-04 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
WO2019126071A1 (en) * 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
DK3773713T3 (da) 2018-04-06 2025-08-18 Regeneron Pharma Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0321196A3 (en) 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. 780 t-dna gene transcription activator
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE144281T1 (de) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh Hefezellen der gattung-schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE174058T1 (de) 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1994005332A2 (en) * 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
WO1995014930A1 (en) 1993-11-23 1995-06-01 Genentech, Inc. Kinase receptor activation assay
US5643748A (en) * 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
CA2218529A1 (en) * 1995-05-08 1996-11-14 Chiron Corporation Nucleic acids for treating obesity
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
ATE307887T1 (de) * 1996-01-08 2005-11-15 Genentech Inc Ob-rezeptor und liganden

Also Published As

Publication number Publication date
EP1619250B1 (en) 2009-11-25
US20020193571A1 (en) 2002-12-19
DE69734443T2 (de) 2006-07-13
JP5525770B2 (ja) 2014-06-18
CA2241564C (en) 2013-09-03
JP2012210211A (ja) 2012-11-01
JP2000503204A (ja) 2000-03-21
DE69739677D1 (de) 2010-01-07
AU721129C (en) 1997-08-01
IL175399A0 (en) 2006-09-05
AR052374A2 (es) 2007-03-14
AR051505A2 (es) 2007-01-17
IL125073A0 (en) 1999-01-26
AU721129B2 (en) 2000-06-22
ATE449849T1 (de) 2009-12-15
EP1619250A1 (en) 2006-01-25
EP0885299B1 (en) 2005-10-26
ATE307887T1 (de) 2005-11-15
DE69734443D1 (de) 2005-12-01
WO1997025425A1 (en) 1997-07-17
IL175399A (en) 2010-12-30
JP2009278987A (ja) 2009-12-03
EP0885299A1 (en) 1998-12-23
CA2241564A1 (en) 1997-07-17
AU1574797A (en) 1997-08-01

Similar Documents

Publication Publication Date Title
AR005397A1 (es) Anticuerpo agonista monoclonal que se liga especificamente al receptor ob, un metodo para mejorar la proliferacion o diferenciacion in vitro de una celula que comprende un receptor ob, el uso de un anticuerpo agonista anti-receptor ob para la preparacion de una dosificacion fisiologicamente aceptable, y metodos para identificar un anticuerpo que se liga o activa al receptor ob que incrementa la proliferacion o diferenciacion de una celula
Pance et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins
US6084075A (en) Agonist and antagonist antibodies to the chemokine receptor-2 (CCR2)
Vlodavsky et al. Aortic endothelial cells synthesize basic fibroblast growth factor which remains cell associated and platelet‐derived growth factor‐like protein which is secreted
Williams et al. The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1.
Ruoslahti et al. Two active sites with different characteristics in fibronectin
Magdesian et al. Infection by Trypanosoma cruzi: identification of a parasite ligand and its host cell receptor
Klein Cytokine-binding proteins: stimulating antagonists
Segal et al. The subclass specificity for the binding of murine myeloma proteins to macrophage and lymphocyte cell lines and to normal spleen cells
Li et al. Receptor-selective variants of human vascular endothelial growth factor: generation and characterization
UA40611C2 (uk) Імунокон'югат, спосіб його виготовлення, фармацевтична композиція
KR930017919A (ko) Cd40 b-세포 항원에 대한 역-수용체 및 이에대한 리간드
Piotrowicz et al. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells
KR970706307A (ko) 인체 결장암 관련 항원에 대한 단일클론성 항체 및 그 용도(monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor)
HUT63204A (en) Process for producing monoclonal antibodies against human tumor necrosis alpha-factor
CA2635963A1 (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
KR870700100A (ko) 최소한 일부분이 알려진 뉴클레오티드 암호서열 또는 아미노산 서열을 갖는 프로테인 또는 펩티드에 상보적인 폴리펩티드와 이것의 디자인 방법
Venetz et al. Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies
Gregory et al. Luteinizing hormone release from dissociated pituitary cells by dimerization of occupied LHRH receptors
KR930700140A (ko) 신생물 질환 치료를 위한 항체 결합체
Moyle et al. A circular antibody-antigen complex is responsible for increased affinity shown by mixtures of monoclonal antibodies to human chorionic gonadotropin.
Allegretta et al. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)
Rubin et al. Hepatocyte adhesion to collagen: isolation of membrane glycoproteins involved in adhesion to collagen
SG59954A1 (en) Improvements in granulocyte-macrophage colony- stimulating factor receptor and derivatives thereof
DK0457804T3 (da) M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop

Legal Events

Date Code Title Description
FG Grant, registration